Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3677-3681

  Doiron, Annie ^a   Yapp, Donald T T ^a   Olivares, Marina ^a   Zhu, Julian X X ^b   Lehnert, Shirley ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; RADIOSENSITIZING AGENT; SEBACIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; DOSIMETRY; GAMMA IRRADIATION; INTRATUMORAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SUSTAINED RELEASE PREPARATION;

ANIMALS; BROMODEOXYURIDINE; DECANOIC ACIDS; DRUG CARRIERS; DRUG IMPLANTS; FEMALE; GAMMA RAYS; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; POLYESTERS; POLYMERS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 0033179683     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bagshaw, M. A., Doggett, R. L., Smith, K. C., Kaplan, H. S., and Nelsen, T. S. Intra-arterial 5-bromodeoxyuridine and x-ray therapy. Am, J. Roentgenol., 99: 886-894, 1967.
2. Jones, G. D. D., Ward, J. F., Limoli, C. L., Moyer, D. J., and Aguilera, J. A. Mechanisms of radiosensitization in iododeoxyuridine-substituted cells. Int. J. Radiat. Biol., 67: 647-653, 1995.
3. Lawrence, T. S., Davis, M. A., Maybaum, J., Stetson, P. L., and Ensminger, W. D. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int. J. Radiat. Oncol. Biol. Phys., 18: 1393-1398, 1990.
4. Miller, E. M., Fowler, J. F., and Kinsella, T. J. Radiosensitization by halogenated pyrimidines: radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat. Res., 132: 81-89, 1992.
5. Uhl, V., Phillips, T. L., Ross, G. Y. Bodell, W. J., and Rasmussen, J. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys., 22: 489-494, 1992.
6. Phillips, T. L., Levin, V. A., Ahn, D., Gutin, P. H., Davis, R. L., Wilson, C. B., Prados, M. D., and Wara, W. M. Evaluation of bromodeoxyuridine in glioblastoma rnultiforme. A Northern California Cancer Center phase II study. Int. J. Radiat. Oncol. Biol. Phys., 21: 709-714, 1991.
7. Prados, M. D., Scott, C. B., Rotman, M., Rubin, P., Murray, K., Sause, W., Asbell, S., Comis, R., Curran, W., Nelson, J., Davis, R. L., Levin, V. A., Lamborn, K., and Phillips, T. L. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group Trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys., 40: 653-659, 1998.
8. Robertson, J. M., Sondak, V. K., Weiss, S. A., Sussman, J. J., Chang, A. E., and Lawrence, T. S. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int. J. Radiat. Oncol. Biol. Phys., 31: 87-92, 1995.
9. Cook, J. A., Glass, J., Lebovics, R., Bobo, H., Pass, H., DeLaney, T. F., Oldfield, E. H., Mitchell, J. B., Glatstein, E., and Goffman, T. E. Measurement of thymidine replacement in patients with high-grade gliomas, head and neck tumors, and high-grade sarcomas after continuous intravenous of 5-iododeoxyuridine. Cancer Res., 52: 719-725, 1992.
10. Rodriguez, R., Ritter, M. A., Fowler, J. F., and Kinsella, T. J. Kinetics of cell Labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int. J. Radiat. Oncol. Biol. Phys., 29: 105-113, 1994.
11. Kinsella, T. J., Collins, J., Rowland, J., Klecker, R., Wright, D., Katz, D., Steinberg, S. M., and Glatstein, E. Pharmacology, and Phase I/II of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastome multiforme. J. Clin. Oncol., 6: 871-879, 1988.
12. Langer, R. New methods of drug delivery. Science (Washington DC), 249: 1527-1533, 1990.
13. Leong, K. W., Brott, B. C., and Langer, R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. Biomed. Mat. Res. 19: 941-955; 1985.
14. Leong, K. W.; D'Amore, P.; Marietta, M. Langer, R. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J. Biomed. Mater. Res. 20: 51-64; 1986.
15. Walter, K. A., Cahan, M. A., Our, M. Tyler, B., Hilton, J., Colvin, O. M., Burger, P. C., Domb, A., and Brem, H. Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res., 54: 2207-2212, 1994.
16. Sipos, E. P., Witham, T. F., Ratan, R., Baraban, J., and Brem, H. Buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when delivered locally in the intracranial 9L-glioma model. Proc. Am. Assoc. Cancer Res., 36: 308, 1995.
17. Brem, H., Mahaley, S., Vick, N. A., Black, K. L., Schold, C. S., Burger, P. C., Friedman, A. H., Ciric, I. S., Eller, T. W., Cozzens, J. W., and Kenealy, J. N. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg., 74: 441-446, 1991.
18. Williams, J. A., Dillehay, L. E., Tabassi, K., Sipos, E., Fahlman, C., and Brem, H. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J. Neuro-oncol., 32: 181-192, 1997.
19. Brem, H., Piantadosi, S., and Burger, P. C. The safety of BCNU-loaded chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas. J. Neuro-oncol., 26: 111-123, 1995.
20. Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K. L., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., Clifford, S., and Schold, C. S. Placebo-controlled trial of safety and efficacy of intra-operative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet, 345: 1008-1012, 1995.
21. Yapp, D. T. T., Lloyd, D. K., Zhu, J., and Lehnert, S. M. Tumor treatment by sustained intra-tumoral release of cisplatin: effects of drug alone and combined with radiation. Int. J. Radiat. Oncol. Biol. Phys., 39: 497-504, 1997.
22. Yapp, D. T. T., Lloyd, D. K., Zhu, J., and Lehnert, S. M. Cisplatin delivery by biodegradable polymer implant, systemic injection and osmotic pump: differences in selected tissue distribution in C3H mice bearing subcutaneous RIF-1 Tumors. Anticancer Drugs, in press, 1999.
23. Yapp, D. T. T., Lloyd, D. K., Zhu, J., and Lehnert, S. M. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int. J. Radiat. Oncol. Biol. Phys., 42: 413-420, 1998.
24. Ramsey, J., Suit, H. D., Preffer, F. I., and Sedlacek, R. Changes in bramodeoxyuridine labeling index during radiation treatment of an experimental tumor. Radiat. Res., 116: 453-461, 1988.
25. Twentyman, P. R., Brown, M. J., Gray, J. W., Franko, A. J., Scoles, M. A., and Kallman, R. F. A new mouse model system (RIF-1) for comparison of endpoint studies. J. Natl. Cancer Inst., 64: 595-604, 1980.
26. Lawrence, T. S., Davis, M. A., Stetson, P. A., Maybaum, J., and Ensminger, W. D. Kinetics of bromodeoxyuridine incorporation by human colon cancer cells in vitro and in vivo. Cancer Res., 54: 2964-2968, 1994.
27. Chui, L. K., Chui, W. J., and Cheng, Y. L. Effects of polymer degradation on drug release: a mechanistic study of morphology and transport properties in 50:50 (dl-lactide-co-glycolide). Int. J. Pharmacol., 126: 169-178, 1995.
28. Williams, J. A., Yuan, X., Dillehay, L. E., Shastri, V. R., Brem, H., and Williams, J. R. Synthetic implantable polymers for local delivery of IUDR to experimental malignant human glioma. Int. J. Radiat. Oncol. Biol. Phys., 42: 631-639, 1998.